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anticoagulant-naïve patients with atrial ﬁbrillation (AF) treated with dabigatran etexilate after its post-approval
availability in Denmark, compared with warfarin.Background Concerns have been raised about an excess of bleeding events or myocardial infarction (MI) among patients treated
with the new oral direct thrombin inhibitor, dabigatran etexilate.Methods From the Danish Registry of Medicinal Product Statistics, we identiﬁed a dabigatran-treated group and a 1:2
propensity-matched warfarin-treated group of 4,978 and 8,936, respectively. Comparisons on efﬁcacy and
safety outcomes were made on the basis of Cox-proportional hazards models stratiﬁed on propensity-matched
groups.Results Stroke and systemic embolism were not signiﬁcantly different between warfarin- and dabigatran-treated patients.
Adjusted mortality was signiﬁcantly lower with both dabigatran doses (110 mg b.i.d., propensity-match group
stratiﬁed hazard ratio [aHR]: 0.79, 95% conﬁdence interval [CI]: 0.65 to 0.95; 150 mg b.i.d., aHR: 0.57, 95% CI: 0.40
to 0.80), when compared with warfarin. Pulmonary embolism was lower compared with warfarin for both doses of
dabigatran. Less intracranial bleeding was seen with both dabigatran doses (110 mg b.i.d., aHR: 0.24, 95% CI: 0.08
to 0.56; 150 mg b.i.d., aHR: 0.08, 95% CI: 0.01 to 0.40). The incidence of MI was lower with both dabigatran doses
(110 mg b.i.d., aHR: 0.30, 95% CI: 0.18 to 0.49; 150 mg b.i.d., aHR: 0.40, 95% CI: 0.21 to 0.70). Gastrointestinal
bleeding was lower with dabigatran 110 mg b.i.d. (aHR: 0.60, 95% CI: 0.37 to 0.93) compared with warfarin but not
dabigatran 150 mg b.i.d. The main ﬁndings were broadly consistent in a subgroup analysis of dabigatran users
with 1-year follow-up (median follow-up 13.9 months [interquartile range: 12.6 to 15.3 months]).Conclusions In this “everyday clinical practice” post-approval nationwide clinical cohort, there were similar stroke/systemic
embolism and major bleeding rates with dabigatran (both doses) compared with warfarin. Mortality, intracranial
bleeding, pulmonary embolism, and MI were lower with dabigatran, compared with warfarin. We found no evidence
of an excess of bleeding events or MI among dabigatran-treated patients in this propensity-matched comparison
against warfarin, even in the subgroup with 1-year follow-up. (J Am Coll Cardiol 2013;61:2264–73) ª 2013 by
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2265quest for new OACs that would be safe and effective
alternatives to warfarin (1,2).
The new oral direct thrombin inhibitor, dabigatran etex-
ilate, has been available in Denmark in 2 doses (either 150 mg
b.i.d. or 110 mg b.i.d.) since August 2011 for stroke preven-
tion inAFpatients with 1 ormore risk factors. The approval of
this new OAC was based on the large Phase 3 clinical trial of
stroke prevention in AF, the RE-LY (Randomized Evalua-
tion of Long-Term Anticoagulant therapy) study (3). This
trial compared 2 doses of dabigatran etexilate against warfarin
in AF patients with 1 or more stroke risk factors and reported
that dabigatran 110 mg b.i.d. was noninferior to warfarin for
the primary endpoint of stroke and systemic embolism, with
20% less major bleeding events, whereas dabigatran 150 mg
b.i.d. showed superiority for the primary efﬁcacy endpoint
over warfarin, with a similar rate of major bleeding (3). In the
RE-LY trial, there were some concerns over a numerical
increase in myocardial infarction (MI) events among
dabigatran-treated patients, and after its introduction, various
reports of major, trauma-related, and fatal bleeding events
were published (4–7), leading to cautionary recommendations
from some regulatory authorities.
The principal objective of this nationwide cohort study
was to assess the efﬁcacy and safety in an “everyday clinical
practice” population of patients with AF treated with dabi-
gatran etexilate after its post-approval availability in
Denmark, compared with patients treated with warfarin. As
a secondary objective, we investigated the feasibility of using
linked healthcare databases for continuous surveillance of the
beneﬁt-risk balance after approval of a new indication.Methods
Study design. For this study we used information from 3
well-established (and well-validated) Danish nationwide
datasets: the Danish Civil Registration system (8); the
National Patient Register (9); and the Danish National
Prescription Registry (10). The application of this nation-
wide cohort approach has recently been described in AF
studies (11,12).
Information on birthday, sex, vital status, and emigration
was available from the Danish Civil Registration System.
The Danish National Patient Register, which was estab-
lished in 1977, includes more than 99% of all discharges
from public and private Danish medical hospitals and holds
information on the dates of hospital admission and dis-
charge and up to 20 discharge diagnoses, classiﬁed according
to the Danish version of the International Classiﬁcation of
Diseases (ICD). In this study we used the 10th Revision
(ICD-10). Also, all prescription drugs sold in Denmark
since 1994 are registered in the Register of Medicinal
Products Statistics maintained by the Danish Health and
Medicines Authority and made available for research in the
Danish National Prescription Registry. The availability of
the unique personal identiﬁcation number enables full
linkage between the datasets. This study based onprescription data was updated up
to June 30, 2012, and the infor-
mation on hospital admissions
and vital status was updated to
December 31, 2012.
To be included in the treat-
ment group of this study, treat-
ment for AF with dabigatran
etexilate (110-mg or 150-mg
b.i.d. doses) should have been
initiated after August 1, 2011. At
that time dabigatran etexilate was
formally approved and available
for AF stroke prevention in
Denmark. Transition to warfarin,
emigration, or end-of-study (De-
cember 31, 2012) were considered as censoring events. A
control group with initiated warfarin treatment between
August 1, 2009, and June 30, 2010 was identiﬁed for
comparison. To avoid treatment-dependent censoring
December 31, 2010, was considered end-of-study for the
control group. All included patients in both time periods were
previously untreated (both warfarin and dabigatran) patients
with AF.
Admissions relevant to this study were found with ICD-10
for admissions reﬂecting efﬁcacy (thrombosis) and safety
(bleeding or death) as well as comorbidity (see following).
The Danish National Prescription Registry was used to
identify the anticoagulant treatment history as well as use of
contraindicated or potential hazardous medication at baseline
and after initiated dabigatran medication for the case group.
For all medications indicating comorbidities (Online Table 1)
except warfarin and dabigatran, baseline medication status was
achieved if the time lapse between the dates of the last
prescription to baseline was shorter than the number of daily
dosages included in the last prescription. For all contra-
indicated or potentially hazardous medication usage, this was
coded if a prescription during the observation period (warfarin
or dabigatran treatment period)was observed (OnlineTable 2).
It was assumed that the dabigatran and warfarin treatment
period was initiated at time of diagnosis. Treatment was
assumed to be lifelong, and hence, treatment was assumed to
end only if a prescription of an alternative was registered.
Patients with mechanical heart valves as well as previous
diagnoses of pulmonary embolism (PE), deep vein throm-
bosis, or mitral stenosis were excluded. Also, the patient was
required to have permanent residence or be immigrated no
later than 1 year before initiation of the treatment.
Outcomes. The primary study outcomes were stroke,
systemic embolism, and intracranial bleeding. Secondary
outcomesweredeath fromany cause, gastrointestinal bleeding,
traumatic intracranial bleeding, or major bleeding (Online
Table 3). The deﬁnition of major bleeding is bleeding from
or into an organ or a sudden drop in hemoglobin leading to
hospital stay. Other outcomes were MI, PE, and hospital stay
for whichever cause, except ambulatory visits related to AF.
Larsen et al. JACC Vol. 61, No. 22, 2013
Efficacy and Safety of Dabigatran in AF Patients June 4, 2013:2264–73
2266Statistical analysis. Baseline characteristics of the dabiga-
tran- and warfarin-treatment populations were reported by
means and SDs for quantitative information and with
frequencies and percentages for qualitative characteristics.
Dabigatran patients were matched 1:2 with patients
selected randomly with no replacement from the control
group with propensity score matching on the basis of the
nearest neighbor in terms of Mahalanobis distance between
the propensities for treatment type and for dabigatran dose
(13). The propensity score models were obtained by logistic
regressions. The ﬁrst model on treatment type (warfarin or
dabigatran) choice was based on the 2011 to 2012 pop-
ulation of warfarin and dabigatran patients; the latter model
on dabigatran dose was based on all dabigatran patients. In
both cases the following baseline information was included
in the regression model: previous stroke, intracranial
bleeding, or transient ischemic attack; heart failure; MI;
diabetes mellitus; renal disease; and hepatic disease. Also, we
included usage indicators of aspirin, clopidogrel, angiotensin
receptor blocker/angiotensin converting enzyme inhibitor,
beta-blocker, amiodarone, statins, proton-pump inhibitors,
and H2-receptor antagonists, respectively. These comor-
bidities comprise both stroke and bleeding risk factors. All
effects were included with interaction with sex and age
category (<65, 65 to 69, 70 to 74, 75 to 79, 80 to 84, 85
years). These models were subsequently used to calculate the
propensity for the treatment type and dose on the warfarin
control population (2009 to 2010) and likewise for the
dabigatran population. The matching was evaluated by
reporting standardized distances between baseline charac-
teristics of the treatment and control populations for each
dose (14).
Incidence rates were calculated for all outcomes. Hazard
ratios (HR) for dabigatran 110 mg and 150 mg versusFigure 1 Inclusion of the Study Population
AF ¼ atrial ﬁbrillation; DVT ¼ deep vein thrombosis; PE ¼ pulmonary embolism.warfarin on the basis of Cox proportional hazards model
stratiﬁed in match groups were calculated with time since
treatment initiation as time-scale (15). Crude HRs are
provided for comparison. The analyses were performed with
SAS/STAT software (version 9.2 for Windows, SAS Insti-
tute, Cary, North Carolina). The Cox regressions were per-
formed with PROC PHREG (SAS). The propensity score
models were estimated with PROC LOGISTIC (SAS).
Our study is not a randomized trial but is a nationwide
cohort study sized with a case and control population of
approximately 5,000 and 9,000 patients, respectively. The
main endpoint of interest is stroke/thromboembolism,
which in a Danish AF population has a 6-month incidence
rate of approximately 4% (Olesen et al. [12] report 4.75% for
1-year follow-up for patients with CHADS2 score ¼ 1).
With power 80% and 5% signiﬁcance level, our study would
be able to detect rate ratios down to 25%.Results
Characteristics of the cohort. Given the focus was on the
treatment-naïve patients in the 2 study periods, we initially
identiﬁed 13,131 and 18,654 patients, respectively. After
excluding existing mechanical heart valves or previous PE,
venous thromboembolism, and mitral stenosis and the
requirement for at least 1 year residence in Denmark, we
identiﬁed a warfarin-treated group and a dabigatran-treated
group of n ¼ 8,936 and n ¼ 4,978, respectively (Fig. 1).
Baseline characteristics are shown in Table 1. The median
follow-up period after incident AF was 10.5 months (IQR:
7.9 to 13.4 months), with no patients lost to follow-up.
Of the dabigatran-treated patients, 32% had a follow-up
of 1 year, and overall this analysis was based on 4,086
patient-years of experience with dabigatran treatment.
Table 1 Baseline Characteristics According to Treatment Group
2009–2010*
2011–2012y
RE-LY Trial All
(n ¼ 18,113)
Warfarin
(n ¼ 8,936)
Warfarin and
Dabigatran All
(n ¼ 14,267)
Dabigatran,
150 mg
(n ¼ 2,239)
Dabigatran,
110 mg
(n ¼ 2,739)
Warfarin
(n ¼ 9,289)
Age, yrs 69.7  12.5 70.8  12.1 67.4  8.5 74.7  11.8 70.4  12.6 71.8  8.7
65 70.0 (6,242) 73.8 (10,524) 68.6 (1,536) 80.5 (2,206) 73.0 (6,782) N/A
75 37.0 (3,295) 38.6 (5,508) 18.3 (410) 52.8 (1,445) 39.3 (3,653) N/A
80 20.1 (1,797) 23.0 (3,275) 2.4 (54) 40.9 (1,121) 22.6 (2,100) N/A
85 7.6 (670) 10.1 (1,437) 0.8 (19) 19.7 (540) 9.5 (878) N/A
Female 40.2 (3,595) 43.5 (6,203) 38.5 (861) 53.1 (1,455) 41.9 (3,887) 36.4 (6,599)
CHADS2z 1.17  1.18 1.16  1.18 0.96  1.07 1.27  1.27 1.18  1.17 2.13  1.13
CHADS2 3–6 14.2 (1,271) 14.3 (2,047) 9.5 (212) 18.9 (518) 14.2 (1,317) 32.5 (5,882)
Prior stroke, transient ischemic attack,
or systemic embolism
17.3 (1,542) 16.1 (2,297) 17.1 (383) 17.5 (478) 15.5 (1,436) 20.0 (3,623)
Heart failure 8.5 (764) 8.3 (1,179) 5.2 (116) 6.9 (188) 9.4 (875) 32.0 (5,793)
Myocardial infarction 9.6 (861) 9.5 (1,362) 6.1 (136) 8.0 (218) 10.9 (1,008) 16.6 (3,005)
Diabetes mellitus 12.3 (1,099) 12.0 (1,713) 12.1 (270) 10.8 (295) 12.4 (1,148) 23.3 (4,221)
Hypertension 19.3 (1,721) 20.9 (2,977) 22.7 (509) 18.0 (493) 21.2 (1,975) 78.3 (14,183)
Moderate/severe renal disease 4.0 (354) 3.9 (552) 1.2 (27) 2.0 (55) 5.1 (470) N/A
Moderate/severe hepatic disease 0.3 (29) 0.2 (34) 0.0 (0) 0.2 (6) 0.3 (28) N/A
Medications in use at baseline
Aspirin 37.4 (3,346) 34.7 (4,946) 35.2 (789) 30.7 (841) 35.7 (3,316) 39.8 (7,198)
Clopidogrel 3.2 (288) 5.3 (756) 5.0 (111) 5.3 (144) 5.4 (501) N/A
ARB or ACE inhibitor 34.8 (3,106) 36.6 (5,226) 39.9 (894) 34.5 (945) 36.4 (3,387) 66.1 (11,979)
Beta-blocker 19.7 (1,757) 20.0 (2,848) 20.9 (468) 16.6 (454) 20.7 (1,926) 62.8 (11,375)
Amiodarone 0.7 (58) 0.5 (70) 0.2 (9) 0.2 (4) 0.6 (57) 10.7 (1,933)
Statinx 27.2 (2,433) 29.8 (4,248) 32.3 (724) 27.2 (745) 29.9 (2,779) 44.4 (8,038)
Proton-pump inhibitor 9.4 (838) 12.7 (1,805) 12.0 (268) 14.4 (395) 12.3 (1,142) 13.8 (2,491)
H2-receptor antagonist 0.2 (20) 0.1 (9) 0.0 (1) 0.1 (2) 0.1 (6) 4.0 (722)
Rate of discontinuation for dabigatran d d 6.5 (145) 3.2 (92) d N/A or N/C
Values are mean  SD or % (n). Baseline deﬁned as date of atrial ﬁbrillation. *The warfarin control period data are from August 1, 2009 to June 30, 2010. yAugust 1, 2011 to June 30, 2012 is the period
used to capture dabigatran data and to derive the propensity score. All dabigatran-treated patients for this analysis were warfarin-naïve. zThe CHADS2 score is a measure of the risk of stroke in which
congestive heart failure, hypertension, an age of 75 years or older, and diabetes mellitus are each assigned 1 point and previous stroke or transient ischemic attack is assigned 2 points; the score is
calculated by summing all the points for a given patient. xStatins are deﬁned here as 3-hydroxy-3-methylglutaryl–coenzyme A reductase inhibitors.
ACE ¼ angiotensin converting enzyme; ARB ¼ angiotensin receptor blocker.
JACC Vol. 61, No. 22, 2013 Larsen et al.
June 4, 2013:2264–73 Efficacy and Safety of Dabigatran in AF Patients
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Danish cohort were broadly similar in age (70.8 years vs.
RE-LY: 71.8 years), sex distribution (43.5% vs. RE-LY:
36.4%), and proportion who were secondary prevention
(16.1% vs. RE-LY: 20.0%) but were overall at lower stroke
risk (mean CHADS2 score of 1.16 vs. RELY: 2.13) and had
fewer comorbidities (e.g., heart failure, prior MI, diabetes
mellitus, hypertension) (Table 1). Moderate/severe renal
impairment was present in 3.9% of the Danish cohort.
Evaluation of propensity-matched cohort. The logistic
regressions for the propensity score models achieved
c-statistics of 0.6 and 0.8 for discriminating between
warfarin and dabigatran groups and between dabigatran
doses. The matched cohorts were compared on baseline
characteristics (Online Table 4). The standardized distances
ranged between 16.8% and 18.8% with average absolute
distance of 6.7%. The dabigatran 110-mg b.i.d. group was
matched to a slightly younger warfarin-treated group, with
less frequent renal impairment. Both dabigatran-treated
groups were compared with a warfarin group with less
frequent treatment with proton-pump inhibitors.Primary study outcomes. The primary study outcomes in
terms of stroke and systemic embolism were similar in the
warfarin group and in the dabigatran etexilate group in the
adjusted analyses (Fig. 2).
In the adjusted analyses, mortality was signiﬁcantly lower in
the dabigatran 110-mg b.i.d. group versus warfarin users
(propensity-match group stratiﬁed hazard ratio [aHR]: 0.79,
95% conﬁdence interval [CI]: 0.65 to 0.95) (Fig. 2) and also in
the dabigatran 150-mg b.i.d. group compared with warfarin
(aHR: 0.57, 95% CI: 0.40 to 0.80). Overall, 8 deaths were
reported to the Danish Health and Medicines Authorityd7
of these 8 patients were>80 years of age (1 was a 76-year-old
man taking dabigatran 150 mg b.i.d.); 6 of the 8 were female,
and 7 of the 8 were taking dabigatran 110 mg b.i.d.
Secondary outcomes. Compared with warfarin, major
bleeding was comparable with both dabigatran doses (p ¼
0.21). The incident event rates of intracranial and traumatic
intracranial bleeding were low (Table 2) and lower intra-
cranial bleeding rates were seen with both dabigatran doses
(110 mg b.i.d., aHR: 0.24, 95% CI: 0.08 to 0.56; 150 mg
b.i.d., aHR: 0.08, 95% CI: 0.01 to 0.40) (Fig. 2).
Stroke
Systemic embolism
Death
Myocardial infarction
Pulmonary embolism
Intracranial bleeding
Gastrointestinal bleeding
Major bleeding
Hospitalization
Crude
Adjusted
Crude
Adjusted
Crude
Adjusted
Crude
Adjusted
Crude
Adjusted
Crude
Adjusted
Crude
Adjusted
Crude
Adjusted
Crude
Adjusted
Outcome / Model
0.01 0.20 1.00 5.00
dabigatran 110mg warfarin
Favors Favors
Warfarin vs dabigatran 110mg
0.79 (0.59; 1.03)
0.73 (0.53; 1.00)
0.78 (0.29; 1.78)
0.60 (0.19; 1.60)
1.02 (0.87; 1.20)
0.79 (0.65; 0.95)
0.41 (0.26; 0.62)
0.30 (0.18; 0.49)
0.42 (0.18; 0.87)
0.33 (0.12; 0.74)
0.30 (0.12; 0.63)
0.24 (0.08; 0.56)
0.67 (0.43; 0.99)
0.60 (0.37; 0.93)
0.88 (0.66; 1.14)
0.82 (0.59; 1.12)
0.51 (0.48; 0.55)
0.53 (0.49; 0.57)
Hazard ratio (95% CI)
0.01 0.20 1.00 5.00
dabigatran 150mg warfarin
Favors Favors
Warfarin vs dabigatran 150mg
0.99 (0.74; 1.30)
1.18 (0.85; 1.64)
0.67 (0.20; 1.73)
1.00 (0.26; 3.35)
0.38 (0.28; 0.49)
0.57 (0.40; 0.80)
0.36 (0.20; 0.59)
0.40 (0.21; 0.70)
0.31 (0.09; 0.75)
0.24 (0.06; 0.72)
0.06 (0.01; 0.29)
0.08 (0.01; 0.40)
0.81 (0.52; 1.21)
1.12 (0.67; 1.83)
0.65 (0.45; 0.90)
0.77 (0.51; 1.13)
0.76 (0.71; 0.81)
0.86 (0.79; 0.93)
Hazard ratio (95% CI)
0.23
0.092
0.70
0.63
<0.0001
0.0003
<0.0001
<0.0001
0.011
0.004
0.0005
0.0006
0.12
0.075
0.043
0.21
<0.0001
<0.0001
P−value
Figure 2 Main Outcome Measures
Main outcome measures (hazard ratios, 95% conﬁdence interval [CI]). The p value is for the hypothesis of no overall difference between treatments. Adjusted analysis is based
on Cox proportional hazards model stratiﬁed on propensity match groups.
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2268We observed trauma-related bleeding events in 25
patients (21 in warfarin- and 4 in dabigatran-treated
patients, respectively). Gastrointestinal bleeding was not
signiﬁcantly different overall (p ¼ 0.075) between dabiga-
tran- and warfarin-treated patients (Fig. 2) but was signiﬁ-
cantly lower in the dabigatran 110-mg b.i.d. compared with
warfarin (aHR: 0.60, 95% CI: 0.37 to 0.93).
The incidence of MI was low overall and lower with both
dabigatran doses (110 mg b.i.d., aHR: 0.30, 95% CI: 0.18
to 0.49; 150 mg b.i.d., aHR: 0.40, 95% CI: 0.21 to 0.70)
compared with warfarin. The risk of PE was lower in
both the dabigatran doses (110 mg b.i.d., aHR: 0.33, 95%
CI: 0.12 to 0.74; 150 mg b.i.d., aHR: 0.24, 95% CI: 0.06
to 0.72) compared with warfarin. The frequency of all-cause
hospital stays was lower in both the dabigatran doses
(110 mg b.i.d., aHR: 0.53, 95% CI: 0.49 to 0.57; 150 mg
b.i.d., aHR: 0.86, 95% CI: 0.79 to 0.93) compared with
warfarin (Fig. 2).
Subgroup analysis on dabigatran users with ‡1-year
follow-up. Of the dabigatran-treated patients with
a follow-up of 1 year, the primary study outcomes in termsof stroke and systemic embolism were broadly similar to that
seen in the main cohort (Table 3). Median follow-up of this
subgroup was 13.9 months (IQR: 12.6 to 15.3 months).
Mortality was signiﬁcantly lower only in the dabigatran
150-mg b.i.d. group compared with warfarin (aHR: 0.58,
95% CI: 0.35 to 0.92). Major bleeding was comparable with
both dabigatran doses versus warfarin, with point estimates
of 0.74 and 0.66, for dabigatran110 mg b.i.d. and 150 mg
b.i.d., respectively. Gastrointestinal bleeding was also not
signiﬁcantly different but with point estimates of 0.61 and
0.78, respectively. The incidence of MI was lower with both
dabigatran doses, although only statistically signiﬁcant for
dabigatran 110 mg b.i.d. (aHR: 0.50, 95% CI: 0.26 to 0.89)
compared with warfarin.
Prescribing trends. Prescribing trends for dabigatran after
its approval in Denmark showed a rapid increase in
prescriptions among new users, peaking in November 2011,
followed by a slow decline and plateau effect (Fig. 3). Few
patients with moderate/severe renal or liver disease (see
Online Table 1 for deﬁnitions) have been treated with dabi-
gatran: renal disease in 5.1% (warfarin), 2.0% (dabigatran
Table 2 Efﬁcacy and Safety for New Atrial Fibrillation Patients Treated With Dabigatran
Warfarin D150 Matched*
(n ¼ 3996)
Dabigatran 150 mg
(n ¼ 2239)
Warfarin D110 Matched
(n ¼ 4940)
Dabigatran 110 mg
(n ¼ 2739)
Primary endpoints
Stroke 109/3,626/3.0 60/1,722/3.5 157/4,333/3.6 62/2,299/2.7
Systemic embolism 8/3,684/0.2 4/1,758/0.2 18/4,402/0.4 6/2,322/0.3
Intracranial bleeding 27/3,680/0.7 1/1,760/0.1 42/4,398/1.0 6/2,323/0.3
Secondary endpoints
Death from any cause 172/3,689/4.7 52/1,760/3.0 453/4,411/10.3 185/2,326/8.0
Gastrointestinal bleeding 53/3,661/1.5 26/1,749/1.5 90/4,369/2.1 28/2,311/1.2
Traumatic intracranial bleeding 11/3,684/0.3 0/1,760/0 10/4,408/0.2 4/2,324/0.2
Major bleeding 104/3,630/2.9 37/1,744/2.2 151/4,329/ 3.5 65/2,296/2.8
Other endpoints
Myocardial infarction 70/3,650/1.9 15/1,752/0.9 111/4,342/2.6 22/2,316/1.0
Pulmonary embolism 20/3,675/0.5 4/1,760/0.2 36/4,397/0.8 7/2,324/0.3
Hospital stay 2,438/2,082/117.1 1,003/1,129/88.8 2,981/2,534/117.6 970/1,726/56.2
Values are events/total person-year at risk/crude event rate/100 years. *Propensity score matched (Online Table 4).
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2269110-mg), and 1.2% (dabigatran 150-mg). Table 4 shows that
there were few patients who received any concomitant
hazardous drugs or medications with potential interaction
with dabigatran in the study period.Discussion
This is the ﬁrst nationwide report from a large “everyday
clinical practice” post-approval clinical cohort in terms of
efﬁcacy and safety outcomes with warfarin and dabigatran
(110 mg b.i.d., 150 mg b.i.d.). We show that stroke was not
signiﬁcantly different between warfarin- and dabigatran-
treated patients, but adjusted mortality was lower with
both dabigatran doses compared with warfarin. Major
bleeding was not signiﬁcantly different between dabigatranFigure 3
Monthly New Users of Warfarin and Dabigatran
Etexilate for AF
Monthly new users of warfarin and dabigatran etexilate for atrial ﬁbrillation (AF) in
the period August 2009 to June 2012 in Denmark.and warfarin, but intracranial bleeding was markedly lower
with both doses of dabigatran. Myocardial infarction was
also signiﬁcantly lower with dabigatran-treated patients
(both groups) compared with warfarin. These main ﬁndings
remained broadly consistent in a subgroup analysis of
dabigatran users with 1-year follow-up. Thus, we found no
evidence of an excess of bleeding events or MI among
dabigatran-treated patients in this propensity-matched
comparison against warfarin in a large post-approval
registry study, even in the subgroup with 1-year follow-up.
The new oral anticoagulants have been recommended in
recent international guidelines or position statements,
because they offer efﬁcacy, safety, and convenience (16–18).
In the recent 2012 focused update of the ESC guidelines,
novel oral anticoagulants such as dabigatran should be
considered rather than a Vitamin K antagonist, whenever an
oral anticoagulant is indicated (16). Initial global uptake of
dabigatran was marred by case reports on fatal bleedings or
thromboembolism, mostly related to inappropriate pre-
scribing (e.g., in renal failure), as well as bleeding related to
trauma (6,7). Regulatory authorities have even issued
cautionary statements on its use, which were subsequently
followed by reassuring updates highlighting that bleeding
rates associated with new use of dabigatran do not seem to
be higher than bleeding rates associated with new use of
warfarin, consistent with observations from the large clinical
trial used to approve the new drug (i.e., the RE-LY trial)
(19,20). Of note, such initial frequent reporting of adverse
events has previously been encountered with the introduc-
tion of new drugs (the so-called “Weber effect”) (21).
In our cohort, the remarkable compliance with the
medication guidance in Denmark is not coincidental. In
contrast to other countries, the Danish Society of Cardiology
has a policy of very early implementation of guidelines from
the ESC to the equivalent Danish guidelines, and hence,
there is great awareness about the use of dabigatran and the
various safety issues right away from the start. Furthermore,
a formal collaboration between the Danish Health and
Table 3 Subgroup Analysis on Dabigatran Users With More Than 1-Year Follow-Up
Outcome
Warfarin vs. Dabigatran
110 mg b.i.d.
Warfarin vs. Dabigatran
150 mg b.i.d.
p Value*HR 95% CI HR 95% CI
Stroke
Crude 0.95 (0.62–1.41) 1.58 (1.06–2.30) 0.05
Adjusted 0.84 (0.53–1.31) 1.53 (0.96–2.43) 0.15
Death
Crude 0.93 (0.72–1.18) 0.39 (0.25–0.59) <0.0001
Adjusted 0.82 (0.62–1.06) 0.58 (0.35–0.92) 0.03
Myocardial infarction
Crude 0.60 (0.33–1.02) 0.62 (0.30–1.14) 0.10
Adjusted 0.50 (0.26–0.89) 0.74 (0.34–1.48) 0.06
Major bleeding
Crude 0.77 (0.51–1.14) 0.63 (0.36–1.02) 0.12
Adjusted 0.74 (0.47–1.14) 0.66 (0.36–1.14) 0.15
Gastrointestinal bleeding
Crude 0.58 (0.30–1.02) 0.70 (0.34–1.29) 0.15
Adjusted 0.61 (0.30–1.13) 0.78 (0.35–1.59) 0.26
*The p value for the hypothesis of no overall difference between the treatments. Subgroup analysis was performed on n ¼ 1,069 taking dabigatran
110 mg b.i.d. and n ¼ 796 taking dabigatran 150 mg b.i.d.; these patients were matched 1:2 with n ¼ 3,730 taking warfarin (initial dabigatran
prescriptions between August 1, 2011 and December 31, 2011; control population was initiated on warfarin regimen between August 1, 2009 and
December 31, 2009). Median follow-up of this subgroup was 13.9 months (interquartile range: 12.6 to 15.3 months). Adjusted analysis is based on
Cox proportional hazards model stratiﬁed on propensity match groups.
CI ¼ conﬁdence interval; HR ¼ hazard ratio.
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Hospital has led to consecutively issued formal guidance to
all Danish doctors after the introduction of dabigatran to the
Danish prescribing market.
In the RE-LY trial, the rates of the primary outcome
were 1.69%/year in the warfarin group, as compared withTable 4
Contraindicated or Potential Hazardous Co-Medication
for Dabigatran Group
Baseline* Follow-Up
Contraindicated drugs
Systemic ketoconazole <0.1 (1) 0 (0)
Cyclosporine 0 (0) 0 (0)
Itraconazole <0.1 (1) 0.1 (6)
Tacrolimus 0 (0) 0 (0)
Potential hazardous co-medication
Amiodarone 0.3 (13) 3.1 (155)
Dronedarone 0.1 (5) 0.4 (18)
Verapamil 2.1 (105) 4.3 (216)
Quinidiney 0 (0) 0 (0)
Clarithromycin 0.1 (4) 0.9 (42)
Coumarins <0.1 (2) 4.8 (239)
Concomitant drug use that can increase bleeding risk
Aspirin 32.8 (1,630) 16.3 (811)
Thienopyridines (clopidogrel, ticagrelor,
prasugrel)
5.3 (262) 2.9 (141)
Low molecular weight heparins 0.3 (13) 0.3 (14)
Fondaparinux 0 (0) 0 (0)
GP IIb/IIIa antagonists (eptiﬁbatide) 0 (0) 0 (0)
Sulﬁnpyrazone 1.3 (66) 2.3 (114)
NSAIDs 11.7 (585) 21.3 (1,059)
Values are % (n). *Baseline is at start of treatment with dabigatran etexilate. yProbably not in use in
Denmark anymore.
GP ¼ glycoprotein; NSAID ¼ nonsteroidal anti-inﬂammatory drug.1.53%/year in the group that received dabigatran 110 mg
b.i.d. and 1.11%/year with dabigatran 150 mg b.i.d. (22).
For comparison, the present study reported fewer events (in
terms of an event rate/100 person-years), but this might be
reﬂective of the overall lower risk Danish population.
Indeed, the Danish study had a mean CHADS2 score of
1.2, which represents a lower stroke risk cohort compared
with the RE-LY trial participants, where the average
CHADS2 score was 2.1.
When compared with dabigatran 150 mg b.i.d., crude
mortality was higher in the dabigatran 110-mg b.i.d. group,
which was the recommended dose for elderly patients
(>75 years of age); however, in the stratiﬁed or adjusted
analyses, mortality was low and comparable between dabi-
gatran 110 mg b.i.d. and warfarin users. Importantly,
mortality was signiﬁcantly lower with both dabigatran doses
compared with warfarin. Patients prescribed dabigatran
110 mg b.i.d. were older than the warfarin-treated patients,
and associated comorbidities could account in part for higher
crude mortality in this cohort (given the nonrandomized
trial design). Of note, approximately 18% of the patients
>75 years of age were prescribed the 150-mg b.i.d. dose. In
the analysis by Eikelboom et al. (23), there was a signiﬁcant
age interaction for the major bleeding endpoint, with less
beneﬁt on major bleeding apparent for dabigatran 110 mg
b.i.d. in elderly patients compared with the overall trial result.
The EU license is to use the 110-mg b.i.d. dose in elderly
patients (>80 years of age), but in Denmark, prescribing
recommendations suggest an “age >75 years” criterion.
Compared with warfarin, major bleeding was lower with
dabigatran 150 mg b.i.d., whereas lower intracranial
bleeding was seen with both dabigatran doses. The
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trial but might reﬂect the lower risk Danish cohort as well as
the application of prescribing recommendations and guide-
lines, whereby the 150-mg b.i.d. dose was not recommended
in elderly patients or those at high bleeding risk or with
concomitant interacting medications (e.g., verapamil) (16).
Our observation of lower intracranial bleeding with both
doses of dabigatran reﬂects the ﬁndings of the main RE-LY
trial and subsequent analyses (22,24).
Concerns over a numerical (but nonsigniﬁcant) increase in
MI in the RE-LY trial (25) prompted discussions over
whether dabigatran caused more MIs (26) or whether
warfarin was more protective (4,27). Our Danish cohort
provides some reassuring “everyday clinical practice” data that
there was not an excess ofMI, and in fact, the incidence ofMI
was lower with both doses of dabigatran compared with
warfarin, even after adjustments for risk factors and propen-
sity score. Compared with the RE-LY trial, our study cohort
was lower risk and had a lower prevalence of prior MI or risk
factors for the same (e.g., diabetes mellitus, hypertension).
Our “everyday clinical practice” cohort design cannot account
for the possibility that physicians could choose to avoid
dabigatran in patients at higher risk of myocardial ischemia,
although to minimize residual confounding, our ﬁndings still
remain consistent even after adjustments for risk factors (i.e.,
comorbidities, including risk factors for MI) and propensity
scores. Similarly, physicians might be either less likely to put
high-risk patients on a regimen of dabigatran or more likely
to switch them if they perceive them as having unstable
international normalized ratios or being at high risk of
bleeding. As shown in Table 3, thienopyridines were used in
5.3% of the patients at baseline but only in 2.9% during
follow-up. If a higher degree of thienopyridine use should
reﬂect that patients were at higher risk of MI at baseline, this
would be in favor of warfarin, not the opposite (as we have
seen). Also, there is no evidence that adding antiplatelet
therapy reduces MI when added to dabigatran (28).
Another concern from the main RE-LY trial was an excess
of gastrointestinal major bleeding events with dabigatran 150
mg b.i.d. compared with warfarin. Indeed, gastrointestinal
bleeding was the most frequent side effect in the cohort from
reports to theDanishHealth andMedicines Authority, but in
our cohort, there was no signiﬁcant excess of gastrointestinal
bleeding with dabigatran-treated patients compared with
warfarin. This was despite similar proportions of patients in
the RE-LY trial and the Danish cohort being on a regimen of
aspirin or proton pump inhibitors. This could reﬂect that
fewer side effects from warfarin were reported to the author-
ities because warfarin has been on themarket formore than 50
years but re-emphasizes that a register-based, post-marketing
surveillance study is a very powerful tool for surveillance of
newlymarketed drugs, because it makes it possible to compare
2 treatments. When reporting side effects of a new drug, the
risk of surveillance bias is high.
This analysis also gives an insight into prescribing patterns
with dabigatran. There was an initial rapid uptake among newusers after the introduction of the drug, followed by a decline
and a plateau effect. Reassuringly, only a minority of patients
received any concomitant hazardous drugs or medications
with potential interaction with dabigatran in the study period.
However, there was a slight increase in nonsteroidal anti-
inﬂammatory drugs during follow-up.
Our approach to monitoring the uptake of dabigatran for
nonvalvular AF is one alternative for addressing the need for
comparative-effectiveness data shortly after the approval of
a drug or a new indication (29). Although the follow-up
time was relatively short for a traditional academic/analytic
study or trial, this report provides a new approach where, in
a dynamic manner, we can study the introduction of a new
drug treatment and generate data that are of relevance to
regulators and public health ofﬁcials. The objective and
approach is clearly different from a classic cohort study
(29–32). By regularly repeating the analyses conducted in
this study, it would be possible to assess the dynamics of the
uptake by observing changes over time in addition to
improving the precision of the estimates. Furthermore,
variants of this model for an enhanced continuous surveil-
lance of the beneﬁt-risk balance could potentially support
new paradigms for licensing of medicinal products (30,32).
Study limitations. This analysis is limited by its dependence
upon prescribing information (covering both general practice
and hospital data), and selection of treatment options in the
post-dabigatran world will be inﬂuenced by patient charac-
teristics that might relate to outcome. Also, we cannot fully
account for the impact of cardiovascular prevention strategies
(e.g., statin and angiotensin-converting enzyme inhibitor use)
or the differences in all the various subgroups (e.g., moderate-
severe kidney disease was present in 1.2% of dabigatran 150-
mg b.i.d. patients, compared with 5.1% of warfarin), given the
“everyday clinical practice” nontrial setting of this dataset.
Also, event ascertainmentmight be greater inwarfarin-treated
patients, simply because they are seen or communicated with
more frequently in relation to international normalized ratio
checks. However, such an “ascertainment bias” would draw
the conclusion more in a direction in favor of warfarin and not
toward dabigatran.
Because this was not a randomized trial dataset (but a
registry-based cohort study), we had no information on time
in therapeutic range (TTR) for the warfarin-treated patients,
but the data from the present study reﬂect overall and
national “best practice” with regard to anticoagulation with
warfarin. Mean TTR in Denmark during the RE-LY study
was good, at 72% (33), and has been reported to be generally
adequate (>65%) in both hospitals and in general practice
(34). Therefore this is in accordance with the overall average
TTR for Denmark in the RE-LY trial. We also only
included warfarin-naïve patients with incident AF, given the
potential risk of selection bias toward dabigatran (previous
compliance problems, poor TTR, bleeding, and so forth).
Patients with a previous need for anticoagulant treatment
of disorders other than AF were also excluded in the
RE-LY trial. Of note, the RELY trial did not show any
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and warfarin-naïve patients (35).
Datasets from Denmark have been well-validated (10,36)
and used in many previous pharmacovigilance studies
(11,12). Also, prescribing coding from this nationwide
cohort data have been validated for AF and its complica-
tions, although it does not have the individual detail on
blood tests (e.g., serum creatinine, hemoglobin) or other
investigations (e.g., detailed imaging data). For example, the
positive predictive value for ischemic stroke in the Danish
National Registry of Patients was 87.6% (95% CI: 80.1% to
93.1%) (37), and the ICD-10 codes for comorbidity in the
Danish National Registry of Patients are consistently high,
with a positive predictive value between 82% and 100% for
the Charlson comorbidity index conditions (38). Not being
100% means that we could overestimate the study outcome
and the inﬂuence from comorbidity, but this is probably
similar between the treatment groups. Nonetheless, outcome
deﬁnitions (e.g., major bleeding) in this “everyday clinical
practice” cohort study and the RE-LY trial are unlikely to
completely overlap. The outcomes addressed in this study
cover hospital diagnosis (major bleeding, thrombosis, and
stroke) and are not treated by general practitioners. Infor-
mation on death comes from the population register, and
this covers all deaths in Denmark, including those not
referred to hospital. Consequently, these data reﬂect “real
world” use data from an entire country, and no one is ruled
out (except users of dabigatran that were not warfarin-naïve;
see Methods). This should provide the best conditions for
a nondifferential comparison between warfarin and dabiga-
tran, strengthened by our propensity score matching.
Our strength is the 4,086 patient-year experience with
dabigatran treatment from this ﬁrst “everyday clinical prac-
tice” post-approval experience of using dabigatran in a
nationwide cohort study with comprehensive prescribing
data ever since the introduction of the drug for AF in
Denmark only approximately 18 months ago. Long-term
data on efﬁcacy and safety events from dabigatran-treated
patients from the RE-LY trial have recently been presented
(RELY-ABLE), where during 2.3 years of additional treat-
ment after the RE-LY trial (total mean follow-up 4.3 years),
the rates of stroke, MI, and major bleeding remained low on
a regimen of dabigatran and were consistent with those seen
during the RE-LY trial (22). We also did not report (or
compare) dabigatran use with rivaroxaban, because the latter
was approved much later than dabigatran in Denmark, and
low numbers (n ¼ w500) and a much shorter patient-year
experience in our dataset preclude a meaningful analysis.
Finally, we have to a large extent eliminated most possibilities
for residual confounding in this study, by using propensity-
matched analysis. The results of this analysis were also
compared with alternative approaches with risk factor (i.e.,
comorbidity) adjustment and age stratiﬁcation, and similar
results as those reported were found. Excluding matched
pairs with distance above a caliber of 0.2 did not alter the
reported conclusions and HRs.Conclusions
Efﬁcacy in terms of stroke and systemic embolism preven-
tion was similar between warfarin and dabigatran (both
doses), whereas mortality, PE, and MI were lower with both
doses of dabigatran, in this “everyday clinical practice” post-
approval clinical cohort. With regard to safety, major
bleeding was similar between dabigatran and warfarin,
whereas intracranial bleeding was lower with both dabiga-
tran doses, compared with warfarin. Also, the rate of
gastrointestinal bleeding was signiﬁcantly lower in the
dabigatran 110-mg b.i.d. treated groups compared with
warfarin. The previous concerns about an excess of bleeding
events or MI among dabigatran-treated patients were not
evident in this propensity-matched comparison against
warfarin in a large post-approval registry study, even in the
subgroup with 1-year follow-up.
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